The presence of an anion gap in a diabetic patient, especially if associated with evidence of compromised renal function, should prompt clinicians to consider metformin as a contributing factor. This consideration is especially important in patients with severe anion gaps associated with lactic acidosis out of proportion to the patient's clinical presentation.
M easurement of serum electrolytes and determination of acid-base status is beyond routine in today's clinical practice. Th e importance of recognizing and treating disturbances in normal physiology cannot be overstated, as this information can provide clues to the existence of many reversible, yet if left untreated fatal, disease processes. Th e most commonly used scenario for calculating the serum anion gap (AG) is determining the etiology of metabolic acidosis (Table 1) . Disturbances of the AG can be seen in a variety of conditions, and if accurately recognized can yield critical diagnostic information. Presented is a case of compound AG acidosis.
CASE PRESENTATION
A 71-year-old woman with type 2 diabetes mellitus, hypertension, and coronary artery disease presented to the emergency department because of altered mental status. She had been seen in an emergency department 9 days earlier for nausea, emesis, diarrhea, and abdominal pain when her creatinine was 1.8 mg/dL and AG was 20 mEq/L. She was discharged home with antiemetics. Her symptoms persisted and she returned via paramedic transport. She was intubated shortly upon arrival secondary to a decreased level of consciousness and concern for airway protection. Her family denied knowledge of hematemesis, melena, fevers, or chills. Her home medications included potassium 20 mEq daily, Lasix 80 mg twice a day, metformin 850 mg twice a day, Novolin R sliding scale, and metoprolol tartrate 100 mg daily.
On examination, her blood pressure was 100/54 mm Hg; heart rate, 123 beats per minute; respiratory rate, 22 breaths per minute; and temperature, 97.9°F. She was intubated and sedated. She was tachycardic without precordial murmurs and tachypneic on the ventilator with coarse breath sounds bilaterally. Her abdomen was soft with hypoactive bowel sounds and without masses. She had palpable pulses that were equal bilaterally. Key laboratory data are outlined in Table 2 . A transthoracic echocardiogram showed an ejection fraction of 75%, a dilated pulmonary artery, and a suggestion of moderate pulmonary hypertension with a right ventricular systolic pressure of 44.4 mm Hg.
Th e patient was admitted to the intensive care unit for refractory shock, acute respiratory failure, oliguric acute kidney injury, severe AG metabolic acidosis, and presumed Metformin-induced lactic acidosis with emphasis on the anion gap Britton Blough, MD, Amber Moreland, MD, and Adan Mora Jr., MD pancreatitis. Her blood was cultured, and she was started on empiric antibiotics. After fl uid resuscitation, her mean arterial pressure remained low, requiring norepinephrine and stress dose steroids. Her severe lactic acidosis was refractory to a bicarbonate drip. She required an elevated compensatory high minute ventilation and eventually continuous veno-venous hemodialysis. While her lactic acidosis slowly down-trended, it remained abnormally high relative to the degree of her hypoperfused state. A metformin level ordered on admission returned as 2.7 mcg/mL. Th e usual therapeutic metformin blood level is in the range of 0.5 to 2.5 mcg/mL (1) . Th e patient became progressively hypotensive despite aggressive measures. No source of infection could ever be identifi ed and all cultures remained negative. A mesenteric Doppler was unable to visualize vascular structures due to body habitus, and a contrast study could not be performed due to the patient's severe iodine allergy. Her respiratory status deteriorated with decreasing lung compliance. On day 6 of her hospitalization, she remained unstable and a decision was made by the family to withdraw life-sustaining therapy. Th e family declined a postmortem examination.
DISCUSSION
In their article initially describing the clinical implications of the AG, Emmett and Narins defi ned the AG and detailed its utility in evaluating a patient's acid-base status (2) . Th e serum AG is calculated from the laboratory measurement of electrolytes and provides important information regarding a patient's acidbase status. By defi nition, the AG is the diff erence between the measured serum cations and anions: (Na + K) -(Cl + HCO 3 ). Since the infl uence of potassium in regards to the AG is minimal, the equation is accepted as simply the following: (Na) -(Cl + HCO 3 ).
In the hospitalized patient, one of the most common causes of metabolic acidosis is lactic acidosis, which produces an unmeasured anion resulting in an elevated AG. Lactate is formed during gluconeogenesis as a product of pyruvate metabolism. Th is formation requires the presence of the catalytic enzyme lactate dehydrogenase to convert nicotinamide adenine dinucleotide hydrate into nicotinamide adenine dinucleotide. Lactic acid in the serum is buff ered by bicarbonate to lactate, which in turn is converted back to pyruvate in the liver and kidney. An increase in lactic acid can thus be thought of as either an overproduction of lactate in the serum or an underutilization of lactate by the liver. Th e former most commonly results from an inhibition of oxidative metabolism that decreases the available ATP and shunts the reaction to formation of additional lactate. Th e types of lactic acidosis can further be broken down into types A and B (Table 3 ). In general, type A can be attributed to tissue hypoxia or global hypoperfusion, as seen in circulatory collapse or in the setting of increased anaerobic activity (3). Type B lactic acidosis occurs in the absence of tissue hypoperfusion and comprises a heterogeneous group of etiologies, including intoxications, liver failure, malignancy, rare hereditary enzyme defi ciencies, and certain medications, as seen in our patient (4).
Metformin-associated lactic acidosis can occur acutely in an overdose but typically has a more gradual onset in patients with hepatic or renal dysfunction due to decreased excretion. It often presents with nausea, abdominal pain, tachycardia, hypotension, and tachypnea (5) . Th e lactic acidosis from metformin is primarily type B. In an overdose, the lactic acidosis can be compounded by type A when the drug's lactic acid accumulation leads to cardiovascular collapse, tissue hypoperfusion, and hepatic dysfunction.
In 1918, guanidine, the active ingredient of the plant Galega offi cinalis, demonstrated hypoglycemic eff ects in animals and led to the development of the class of drugs known as biguanides. Th ese drugs act to reduce blood glucose levels and insulin concentrations by suppressing basal hepatic gluconeogenesis and improving peripheral tissue insulin sensitivity; however, their association with the development of lactic acidosis has been well reported (5) . Th e biguanides contain two guanide molecules linked together with an elimination of an amino group. In the 1920s, several synthetic biguanides were used clinically, but their toxicities limited their use (6, 7) . Metformin, currently the only biguanide available in the United States, is less associated with lactic acidosis and was not approved until 1995 by the US Food and Drug Administration (8) . Several other more potent biguanides were also developed, including phenformin and buformin, but these were discontinued in many countries by the late 1970s secondary to the development of lactic acidosis (6, 7) .
Metformin lowers blood glucose in multiple ways, including suppression of hepatic gluconeogenesis, increased peripheral insulin-mediated glucose uptake, decreased fatty acid oxidation, and increased intestinal glucose consumption (7). Metformin reaches maximal plasma concentration approximately 2 hours after ingestion, and its half-life ranges from 2.5 to 4.9 hours. Approximately 90% of it is eliminated in the urine in 12 hours (7) . Th e most common side eff ects of metformin use are gastrointestinal, including diarrhea, nausea, vomiting, abdominal bloating, and anorexia. Th ese side eff ects may occur in 20% to 30% of patients receiving this drug, usually at the onset of therapy, but rarely persist (9) . Current contraindications for metformin use include chronic kidney disease (creatinine levels >1.5 mg/dL in men and >1.4 mg/dL in women), liver disease, heart failure, age >65, pulmonary disease, use of intravenous contrast agents within 48 hours, or any condition with relative tissue hypoxia (9) . Lactic acidosis is a rare but serious side eff ect of metformin use. Th e estimated incidence is 6 cases per 100,000 patient-years (9) . Th e presence of metformin-associated hyperlactatemia in critical care patients has been associated with a mortality >30% (10) .
Metformin inhibits mitochondrial cellular respiration, which increases anaerobic metabolism and lactate levels (3). Th is eff ect is most profound in the gut due to its affi nity for intracellular proteins in the gastrointestinal tract (11) . Th e pathophysiology of lactic acidosis from metformin is likely due to inhibition of gluconeogenesis by blocking pyruvate carboxylase, the fi rst step of gluconeogenesis, which converts pyruvate to oxaloacetate. Blocking this enzyme leads to accumulation of lactic acid. Biguanides also decrease hepatic metabolism of lactate and have a negative ionotropic eff ect on the heart, both of which elevate lactate levels (11) . Metformin dose, along with the duration of exposure from accumulation in patients with decreased renal clearance, can cause lactic acidosis (3) . Gradual toxicity, as demonstrated in our patient, is usually multifactorial and related to the drug's decreased renal excretion. Th e lipophilic nature of the drug allows for its accumulation, causing a severe lactic acidosis but only minimally elevated serum drug levels (12) . As previously mentioned, while there is an accepted therapeutic range of metformin, the amount of drug required to cause toxicity is unclear (3). A study by Lalau et al demonstrated that the lactic acidosis seen is not necessarily due exclusively to metformin accumulation (13) . Th is leads to the conclusion that a mixed type of lactic acidosis (A and B) is seen in most cases, and it is the severity of the underlying disease process that determines the overall prognosis (14) .
Hemodialysis continues to be the defi nitive treatment for metformin accumulation leading to toxicity, as 90% of the drug is eliminated via the kidneys. A report by Pearlman et al demonstrated through serial measurements of metformin levels during hemodialysis that the drug can be dialyzed; however, there can be a rebound phenomenon due to its lipophilic properties and increased tissue binding (15) . Despite metformin having minimal protein binding, hemodialysis does not remove large amounts of the drug due to its large volume of distribution. However, hemodialysis does improve acid-base status and clinical outcomes in patients with severe lactic acidosis due to metformin.
Our patient did not have extremely high plasma concentrations of metformin in the setting of profound shock. Th is leads us to the conclusion that she likely had a slow accumulation over a period of days and likely stopped taking the medication at some point prior to her arrival due to her illness. Her severe lactic acidosis was likely of a mixed type from the combination of tissue hypoxia as well as metformin toxicity, both of which contributed to her overall mortality. Although metformin does cause a lactic acidosis, this by itself is not an independent predictor of mortality in these patients.
